India Probes Chinese Penicillin G Imports for Dumping: What the DGTR Initiated and What Comes Next

India's Directorate General of Trade Remedies (DGTR) initiated an anti-dumping investigation into imports of Penicillin G and its salts from China on 28 September 2026. The probe followed an application by Lyfius Pharma Private Limited, which alleges that dumped imports are materially retarding the establishment of its domestic industry. As of 11 October 2026, the investigation has been initiated and is ongoing. The evidence supplied does not show any preliminary or final findings, and no anti-dumping duty has been imposed.

GKToday's report is dated 11 October 2026. That is the source publication date, not the date of the event. The event date is the DGTR initiation notification of 28 September 2026.

Status at a glance (as of 11 October 2026)

What is being investigated

Product under consideration

The notification covers Penicillin G, also called benzylpenicillin, and its salts. Penicillin G is a beta-lactam antibiotic in the penicillin group. The scope includes all forms, grades, strengths and concentrations, whether or not they meet pharmacopeial standards, in solid and liquid form.

The notification says the goods are mainly used as a key starting material (KSM) or active pharmaceutical ingredient (API) for making other APIs. They are also used as an API in finished formulations for bacterial infections such as pneumonia, dental infections, diphtheria and meningitis.

The goods fall under Chapter 29 (Organic Chemicals), heading 2941 (Antibiotics), sub-heading 2941 10 10. The notification says this classification is indicative only and does not bind the scope of the investigation.

Subject country and period

The applicant had alleged dumping from China PR and Hong Kong. DGCI&S data showed no imports from Hong Kong during the period of investigation, so the subject country is China PR alone.

• Period of investigation (POI): 1 April 2025 to 31 March 2026, a 12-month period.
• Injury investigation period: financial years 2022-23, 2023-24 and 2024-25, plus the POI.

Why the DGTR initiated the probe

Prima facie findings

The Designated Authority found sufficient prima facie evidence of dumping, material retardation and a causal link between them. A prima facie finding is only an initial assessment, not a final determination of dumping or injury.

• Dumping margin: Normal value and export price were compared at the ex-factory level. The margin was prima facie positive and above the de minimis level.
• Normal value: The applicant argued that China should be treated as a non-market economy. For initiation, normal value was set on "any other reasonable basis" under Para 7 of Annexure-I to the AD Rules, 1995. This was the domestic industry's adjusted cost of production plus a reasonable amount for selling, general and administrative expenses and profit.
• Export price: It was based on the CIF price in DGCI&S import data, with adjustments for items such as freight, insurance and port expenses.
• Import volume: Subject imports were above de minimis. China accounted for virtually all imports of the goods into India during the POI.

Material retardation, not injury to an established industry

Lyfius Pharma describes itself as an unestablished producer. It claims that dumped imports are holding back the establishment of its domestic industry. It cites low capacity utilisation, performance below expectation, prices cut to match landed import prices, cash losses and negative returns. These are the applicant's claims. The Authority accepted them only as sufficient prima facie evidence for initiation.

Domestic industry: points of difference

The applicant says it is the sole eligible producer in India and that it began production in FY 2024-25. It also claims that earlier Indian Penicillin G production shut down because of dumped imports.

The notification records one other producer, Virchow Petrochemicals Private Limited. The applicant argued that Virchow should be excluded from the domestic industry because of its significant imports. For initiation, the Authority included Virchow and still found that the applicant forms a major proportion of domestic industry under Rule 2(b) of the AD Rules, 1995.

GKToday adds that the Prime Minister inaugurated Lyfius Pharma's Penicillin G facility in Kakinada, Andhra Pradesh, in October 2024. It gives a stated capacity of 15,000 tonnes and says the plant was meant to revive domestic production after a hiatus from the late 1980s. It also says India launched seven anti-dumping investigations against Chinese products between 23 and 28 September 2026, four of them on pharmaceutical products. These details come only from GKToday and are not in the DGTR notification reviewed here.

How the process works

Legal basis and decision chain

The Authority initiated the case under Section 9A of the Customs Tariff Act, 1975 read with Rule 5 of the Customs Tariff (Identification, Assessment and Collection of Anti-Dumping Duty on Dumped Articles and for Determination of Injury) Rules, 1995 (AD Rules, 1995). Rule 6 procedure applies. The Authority will determine the existence, degree and effect of dumping and recommend a duty adequate to remove the injury, if one is levied.

GKToday notes that the DGTR works under the Ministry of Commerce and Industry and recommends duties, while the Ministry of Finance takes the final decision on imposing them. It also notes that an anti-dumping duty needs a finding of dumping, material injury or threat, and a causal link, in line with the WTO Anti-Dumping Agreement.

Submissions and deadlines

• Interested parties must register on the SETU portal and file under case ID AD/OI/057/2026.
• Comments on the scope of the product and the PCN methodology are due within 15 days of transmission of intimation letters.
• Information, including confidential and non-confidential versions, is due within 37 days of that transmission.
• Parties making confidential submissions must also file a non-confidential version.
• If a party does not cooperate, the Authority may record findings on the facts available.

The evidence gives no transmission date for the intimation letters, so the exact deadlines cannot be calculated here. The applicant also asked for preliminary findings and provisional duty under Rule 13. The Authority will consider this only "if and to the extent warranted" at an appropriate stage, so no provisional duty is indicated.

The full text is in the DGTR initiation notification.

Exam-relevant points

• Initiating a probe is not the same as imposing a duty.
• The DGTR recommends; the Ministry of Finance decides on imposition, per GKToday.
• Penicillin G is also called benzylpenicillin.
• The POI is 1 April 2025 to 31 March 2026.
• The case is based on material retardation to the establishment of a domestic industry, not injury to an established one.

FAQ

Has India imposed anti-dumping duty on Chinese Penicillin G?

No duty is reported in the evidence. The DGTR has only initiated an investigation as of 11 October 2026.

Who filed the application?

Lyfius Pharma Private Limited filed it before the DGTR's Designated Authority.

Practice MCQs

Question 1

On what date did the DGTR issue the initiation notification for the anti-dumping investigation into Penicillin G and its salts from China?

1. 23 September 2026
2. 28 September 2026
3. 11 October 2026
4. 31 March 2026

Answer: 28 September 2026 — the DGTR notification is dated 28.09.2026; 11 October 2026 is only GKToday's publication date.

Question 2

What is the period of investigation in the Penicillin G case?

1. 1 April 2022 to 31 March 2023
2. 1 April 2024 to 31 March 2025
3. 1 April 2025 to 31 March 2026
4. 1 January 2026 to 30 September 2026

Answer: 1 April 2025 to 31 March 2026 — the notification sets this 12-month period as the POI.

Question 3

Which body takes the final decision on imposing an anti-dumping duty recommended by the DGTR, according to the source report?

1. Ministry of Finance
2. Lyfius Pharma Private Limited
3. World Trade Organization
4. Designated Authority of the DGTR

Answer: Ministry of Finance — GKToday states that the DGTR recommends while the Ministry of Finance decides on imposition.

Question 4

Why is China PR alone treated as the subject country in this investigation?

1. The applicant did not allege dumping from Hong Kong
2. No imports from Hong Kong were found during the POI in DGCI&S data
3. Hong Kong was found to have no dumping margin
4. Hong Kong is classified under a different customs heading

Answer: No imports from Hong Kong were found during the POI in DGCI&S data — the notification gives this as the reason for dropping Hong Kong despite the applicant's allegation.